Final safety and efficacy data of long-term open-label dosing of subcutaneous (SC) Romiplostim in children with Immune Thrombocytopenia (ITP)

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: 2731c64e53e94f2fe0aa1aec7364e2ad7107151c
First added on: Feb 08, 2025